Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Olatorepatide · HS-20094

Peptide · developed by Regeneron Pharmaceuticals

Phase 2 Most advanced trial
REGN Developer
1 Registered trials

What is Olatorepatide?

Olatorepatide (HS-20094) is a drug studied in hidradenitis suppurativa, with overweight and obesity also listed as trial conditions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
HS-20094
Drug type
Peptide
Therapy area
Metabolic
Developer
Regeneron Pharmaceuticals (REGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
AB29LD7VUQ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07830329 Phase 2 Hidradenitis Suppurativa Recruiting REGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hidradenitis Suppurativa

More from Regeneron Pharmaceuticals

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Olatorepatide

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.